NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Top players featured include known names such as COMPASS Pathways (NASDAQ: CMPS), Silo Pharma (NASDAQ: SILO), Numinus Wellness (OTCMKTS: NUMIF), Cybin (NYSE: CYBN), Mind Medicine (MindMed) (NASDAQ: MNMD), PharmaTher Holdings (OTCMKTS: PHRRF) and atai Life Sciences (NASDAQ: ATAI); yet also general biotech industry heavyweights like Jazz Pharmaceuticals (NASDAQ: JAZZ), Janssen Pharmaceuticals (NYSE: JNJ) and Pfizer (NYSE: PFE).
The global market’s size is predicted to grow at a CAGR of around 14% in the next 12 years, garnering a revenue of $12 billion by the end of 2035, up from 2022’s $3 billion.
Context And Key Takeaways
As most pharmaceutical market projections do, the research contemplates …